SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Aug 25, 2026	Aug 25, 2026	View filing
S-8	Aug 25, 2026	Aug 25, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
8-K	Aug 11, 2026	Aug 11, 2026	View filing
4	Aug 6, 2026	Aug 6, 2026	View filing
SC 13G/A	Jul 30, 2026	Jul 30, 2026	View filing
SC 13G	Jul 30, 2026	Jul 30, 2026	View filing
10-Q	Jul 28, 2026	Jul 28, 2026	View filing
8-K	Jul 28, 2026	Jul 28, 2026	View filing
8-K/A	Jul 22, 2026	Jul 22, 2026	View filing
8-K	Jul 20, 2026	Jul 20, 2026	View filing
4	Jun 25, 2026	Jun 25, 2026	View filing
3	Jun 25, 2026	Jun 25, 2026	View filing
8-K	Jun 25, 2026	Jun 25, 2026	View filing
8-K	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 17, 2026	Jun 17, 2026	View filing
8-K	Jun 17, 2026	Jun 17, 2026	View filing
8-K	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
8-K	May 22, 2026	May 22, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.

Fort Myers, FL

2,500 employees

www.neogenomics.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Anthony Zook

View full financials